CBLI - Cleveland BioLabs, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Cleveland BioLabs, Inc.

73 High Street
Buffalo, NY 14203
United States

Full Time Employees15

Key Executives

Dr. Yakov N. Kogan Ph.D., MBAChief Exec. Officer and Interim Principal Financial Officer287.47kN/A44
Dr. Langdon L. Miller M.D.Pres and Chief Medical Officer193.57kN/A63
Dr. Andrei V. Gudkov Ph.D., D.Sci.Chief Scientific OfficerN/AN/A61
Dr. Ann Lenich Hards Ph.D.Exec. VP of Regulatory AffairsN/AN/AN/A
Dr. Andrei Purmal Ph.D.VP of ChemistryN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company’s advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Corporate Governance

Cleveland BioLabs, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.